INTRODUCTION {#sec1-1}
============

Contrast-enhanced magnetic resonance imaging (MRI) is the diagnostic modality of choice for characterizing brain neoplasms.\[[@ref1]\] High-grade gliomas (HGGs), brain metastases (BM), and primary central nervous system lymphomas (PSNCL) are common high-grade brain malignancies in adults.\[[@ref2]\] Contrast enhancement on T1-weighted images reflects areas of blood-brain barrier breakdown regardless of the pathology.\[[@ref3]\] Advanced MR sequences, such as diffusion-weighted and perfusion imaging, are helpful; however, there still remains a subset of patients with imaging overlap.\[[@ref4]\] Accurate preoperative diagnosis is often crucial because the management and prognosis of these tumors are substantially different. 18F-fluoroethyl-tyrosine (FET) is transported through L-amino acid transporters (LAT), which are present in normal brain parenchyma; and their expression proportionately increases with grade of glial proliferation.\[[@ref5]\] It has been, thereby accepted as standard-of-care for differentiating between high-grade and low-grade glial tumors.\[[@ref6]\] Since all three conditions mentioned above have altogether different management plans, there is an unmet need for a noninvasive modality for differentiating between these lesions. FET-positron-emission tomography (FET-PET) has the potential to specifically detect glial tumors using semi-quantitative parameters;\[[@ref7]\] hence, we conceptualized this study to generate reliable cut-off values by comparing the imaging findings with pathology.

MATERIALS AND METHODS {#sec1-2}
=====================

Patients {#sec2-1}
--------

In this retrospective study design, we included 27 patients \[[Table 1](#T1){ref-type="table"}\], who presented with high-grade brain lesions (tumors belonging to Grades III and IV by the WHO classification of central nervous system \[CNS\] tumors -- 2016 were defined as "high grade") on index MRI, between October 2016 and October 2017, which showed overlapping features for HGG and metastases, HGG and PCNSL, or for all the three tumor types \[[Table 2](#T2){ref-type="table"}\]. These findings were confirmed by two expert neuroradiologists, part of Multidisciplinary Neuro-Oncology Joint Clinic of our Institution, who thereafter advised FET-PET. These patients underwent FET-PET before any therapeutic interventions that might have influenced 18F-FET uptake in the tissue (surgery, biopsy, chemoradiotherapy, or radiosurgery). Furthermore, these patients underwent stereotactic biopsy or open resection within 6 weeks after MR and PET imaging, thus providing definite neuropathological diagnosis. This study design was approved by the Institutional Review Board and Ethics Committee of our Institution (Hospital IRB No -- 3075).

###### 

Patient Characteristics (G-Glioma, M-Metastases, L- Lymphoma)

  Patient No   Age/Sex   Differentials on MR   T/Wm (5 min)   T/Wm (20 min)   Histopathology
  ------------ --------- --------------------- -------------- --------------- ---------------------------------
  1            55/M      G/M                   2.2            2.3             Grade IV, Glioblastoma
  2            58/M      G/L/M                 2.04           2.2             Grade IV, Glioblastoma
  3            55/F      G/L                   2.6            2.2             Grade IV, Glioblastoma
  4            38/F      G/L                   2              2.2             Grade IV, Glioblastoma
  5            21/F      G/L                   1.2            1.1             Tuberculoma
  6            62/M      G/M                   1.8            1.1             Grade IV, Glioblastoma
  7            54/M      G/L/M                 1.6            1.6             Metastases
  8            86/M      G/L                   2.6            2.6             Grade IV, Glioblastoma
  9            62/M      G/L                   2.8            2.6             Grade IV, Glioblastoma
  10           57/M      G/L/M                 2.7            2.6             Grade IV, Glioblastoma
  11           43/F      G/M                   1.5            1.6             Metastases
  12           78/M      G/L/M                 2.4            2.5             Grade IV, Glioblastoma
  13           67/F      G/L                   1.3            1.4             PCNSL
  14           35/M      G/L                   1.8            1.6             Metastases
  15           42/F      G/L/M                 1.4            1.6             Grade III, Anaplasticmeningioma
  16           56/M      G/L/M                 2.3            2.5             Grade IV, Glioblastoma
  17           72/M      G/L/M                 2.6            2.4             Grade IV, Glioblastoma
  18           50/F      G/L/M                 2.1            2.2             Grade IV, Glioblastoma
  19           28/F      G/L/M                 1.5            1.7             PCNSL
  20           34/M      G/L/M                 1.6            1.6             Tuberculoma
  21           81/M      G/M                   2.4            2.5             Grade IV, Glioblastoma
  22           64/M      G/L                   2.1            2.5             Grade IV, Glioblastoma
  23           56/M      G/M                   2.1            2.0             Metastases
  24           48/F      G/L                   1.6            1.8             PCNSL
  25           45/M      G/L/M                 2.8            2.7             Grade IV, Glioblastoma
  26           72/M      G/L/M                 1.2            1.5             Metastases
  27           65/F      G/M                   2.4            2.4             Grade IV, Glioblastoma

###### 

MR imaging features (G-Glioma, M-Metastases, L- Lymphoma)

  Patient No   MR diagnosis   MR findings                                                                
  ------------ -------------- ----------------------- -------------- ---------------- ------------------ ---------------------
  1            G/M            Left temporal           Hypo           Enhancing        Choline Peak       Hypoperfused
  2            G/L/M          Peri-ventricular        Hypo           Enhancing        Choline Peak       Hyperperfused
  3            G/L            Left insular            Hyper          Ring-enhancing   Choline peak       Hyperperfused
  4            G/L            Peri-ventricular        Hypo           Enhancing        Choline peak       Hypoperfused
  5            G/L            Grey-white interface    Central Hypo   Ring-enhancing   Non-contributory   Mild hyperperfusion
  6            G/M            Midline pericallosal    Iso-           Enhancing        Choline Peak       Hypoperfused
  7            G/L/M          Right frontal           Iso            Ring-enhancing   Non-contributory   Hyperperfused
  8            G/L            Right frontal           Hypo           Ring-enhancing   Non-contributory   Hyperperfused
  9            G/L            Periventricular         Iso to hyper   Ring-enhancing   Choline peak       Mild hyperperfusion
  10           G/L/M          Left medial temporal    Hypo           Enhancing        Choline peak       Hypoperfused
  11           G/M            Right parietal          Hypo           Ring-enhancing   Non-contributory   Hyperperfused
  12           G/L/M          Left parieto-temporal   Iso            Ring-enhancing   Non-contributory   Hyperperfused
  13           G/L            Peri-ventricular        Hypo           Enhancing        Choline peak       Hypoperfused
  14           G/L            Left Temporal           Hypo           Ring-enhancing   Non-contributory   Hyperperfused
  15           G/L/M          Left frontal            Iso to hyper   Enhancing        Non-contributory   Hyperperfused
  16           G/L/M          Left temporal           Hypo           Enhancing        Choline Peak       Hypoperfused
  17           G/L/M          Right insular           Hypo           Enhancing        Non-contributory   Hypoperfused
  18           G/L/M          Left frontal            Hypo           Ring-enhancing   Non-contributory   Hypoperfused
  19           G/L/M          Periventricular         Iso to hyper   Ring-enhancing   Choline peak       Hyperperfused
  20           G/L/M          Left Temporal           Hypo           Ring-enhancing   Non-contributory   Hyperperfused
  21           G/M            Peri-ventricular        Hypo           Enhancing        Choline peak       Hypoperfused
  22           G/L            Left insular            Hyper          Ring-enhancing   Non-contributory   Hyperperfused
  23           G/M            Right parietal          Hypo           Ring-enhancing   Non-contributory   Hyperperfused
  24           G/L            Periventricular         Iso            Ring-enhancing   Choline peak       hyperperfused
  25           G/L/M          Right frontal           Iso to hyper   Ring-enhancing   Non-contributory   Hypoperfused
  26           G/L/M          Left frontal            Hypo           Ring-enhancing   Non-contributory   Hyperperfused
  27           G/M            Right temporal          Iso            Ring-enhancing   Choline Peak       Hypoperfused

Iso- Iso-intense, Hypo-hypointense, hyper-hyperintense

Positron-emission tomography imaging {#sec2-2}
------------------------------------

18F-FET was manufactured at in-house medical cyclotron facility. PET studies were acquired after intravenous injection of 222--296 MBq of 18F-FET using dedicated PET/computed tomography (CT) scanners (Philips Astonish Time-of-Flight systems) incorporating 16-slice and 64-slice CT components, respectively. Static acquisition was performed by acquiring limited images with brain in field-of-view at 5 min and 20 min, each for the duration of 5 min.

Image processing {#sec2-3}
----------------

Images were processed and reported by one nuclear medicine physician who was blinded to clinical history and MR findings. Tumor-to-contralateral white mater ratio (T/Wm) was the semi-quantitative parameter used for image analysis. Transaxial slices showing the highest 18F-FET accumulation in the tumors were chosen for the region of interest (ROI) analyses. Three-dimensional volumetric ROI was placed on axial, coronal, and sagittal planes by the nuclear medicine physician \[[Figure 1](#F1){ref-type="fig"}\]. Maximum standardized uptake value (SUV~max~) at the tumor site was derived. Another ROI was placed over contralateral white mater over three consecutive slices, and average of these values was taken as SUV~max~ over contralateral white mater. T/Wm was calculated by dividing the above two parameters (SUV~max~ of tumor and contralateral white mater). All primary brain lesions were subjected to a surgical biopsy or resection for histopathological confirmation. Receiver operating characteristic curve analysis was used to find the optimal T/Wm value that could differentiate glial tumors from other pathologies.

![Region of interest generated over coronal (a), sagittal (b), and axial (c) FET-PET images. Background region of interest drawn over contralateral white mater (d) on axial PET image](WJNM-18-266-g001){#F1}

RESULTS {#sec1-3}
=======

[Table 1](#T1){ref-type="table"} shows the demographic details, MR findings, FET-PET findings, and histopathological results in all patients. This study included 27 patients (male/female: 17/10), with a median age of 56 years (range: 21--86 years). Based on MRI findings, radiological differentials were HGG and PCNSL in nine patients \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\], HGG and metastases in five patients \[[Figure 4](#F4){ref-type="fig"}\], and all three differentials (HGG, PCNSL, and metastases) in 13 patients \[[Figure 5](#F5){ref-type="fig"}\]. On final histopathology, 16 patients were diagnosed with HGG, five with metastases, and three with PCNSL. Two patients had tuberculoma and one had anaplastic meningioma. PCNSL had a low T/Wm (mean of 1.46 at 5 min and 1.63 at 20 min); metastases also had a low T/Wm (mean of 1.64 and 1.66 at 5 and 20 min, respectively). Similarly, other three patients with tuberculoma (mean T/Wm 1.4 and 1.35 at 5 and 20 min) and anaplastic meningioma (T/Wm -- 1.4 and 1.6 at 5 and 20 min) had low T/Wm. However, HGG, all of which were diagnosed as Grade 4 on final histopathology, showed a relatively higher T/Wm with a mean of 2.36 and 2.33 at 5 and 20 min, respectively. Thus, all high-grade nonglial tumors showed a mean T/Wm of 1.52 at 5 min and 1.59 at 20 min, which was significantly lower compared to high-grade tumors of glial origin \[[Figure 6](#F6){ref-type="fig"}\]. T/Wm cutoff of 1.9 at both 5 min and 20 min showed 93.8% sensitivity \[[Figure 7](#F7){ref-type="fig"}\] and 91% specificity to diagnose HGGs; (5 min -- area under the curve (AUC) =0.974, *P* = 0.00, 20 min AUC = 0.940, *P* = 0.00).

![Patient 3 was a 55-year-old female, presented with headache for 1 month, axial MR sequences (arrows) show well-circumscribed mass along the occipital horn of left lateral ventricle, (a) iso-to-hypointense on T2-weighted image (b) enhancing on postcontrast T1-weighted image, with (d) restricted diffusion and (e) low apparent diffusion coefficient, hyperperfusion on MR perfusion sequence; MR spectroscopy was noncontributory. Although features were favoring PCNSL, age and rapid clinical deterioration raised the suspicion of glial tumor. Axial FET-PET (c and f) fused PET/CT images (arrows) showed increased tracer uptake in the mass, with a tumor-to-contralateral white mater ratio of 2.6 and 2.2 at 5 and 20 min. Biopsy was suggestive of the WHO Grade IV glioma -- glioblastoma](WJNM-18-266-g002){#F2}

![An 86-year-old male (patient 8), known case of chronic kidney disease, presenting with headache and limb weakness, underwent a MRI at a regional center; axial images (a) showed an ill-defined T1 hypointense, T2 iso-to-hypointense corpus callosal lesion infiltrating the ventricles and right thalamus, no contrast could be administered, there was facilitated diffusion on diffusion-weighted imaging and ADC map; hyperperfusion on MR perfusion images differentials of PCNSL and high-grade glioma were given. FET-PET showed tumor-to-contralateral white mater (T/Wm) ratio of 2.6 on both 5 (c) and 20 (d) minute images. 5-min image is an index of vascularity, however, since maximum uptake occurs till 20 min, increased 20-min uptake in the hyperperfused lesions seen at 5 min is suggestive of high-grade glioma. Histopathology revealed Grade IV gliomas](WJNM-18-266-g003){#F3}

![Patient 7 is a 54-year-old male, presented with progressive bilateral diminution of vision and right hemiparesis for 2 months, MRI showed (a) T2-hypointense lesion in the left occipital region, with perilesional edema. (b) Axial postcontrast T1-weighted image showed homogeneous enhancement. MR spectroscopy and perfusion were noncontributory. Differentials were high-grade glioma, PCNSL with rare possibility of metastases. FET-PET was done (c), which showed low-grade uptake in the lesion with a tumor-to-contralateral white mater (T/Wm) ratio of 1.6 at 5 and 20 min. Patient was not willing for biopsy; hence, whole-body FDG PET was done which showed rim of increased uptake in the brain lesion (\[d\] equal to gray matter), and primary site in the anal canal, seen on maximum intensity projection (MIP) image (\[e\] -- arrow), biopsy showed anal melanoma, thus brain lesion was most likely metastatic. FET-PET (T/Wm) ratio was useful in ruling out high-grade glioma](WJNM-18-266-g004){#F4}

![Patient 12 was a 78-year-old male presented with memory loss, MRI showed well-defined lesion in the left parietal region (arrows), periventricular location, (a) hyperintense on T2 with edema, (b) T1-postcontrast showed minimal enhancement, (c and d) rim of restricted diffusion and low apparent diffusion coefficient, (e) MR spectroscopy showed choline peak with raised Cho/Cr ratio, and MR perfusion imaging showed relative cerebral blood volume of 158.3 suggestive of mild hyperperfusion. Considering the age and overlapping imaging features, differentials of PCNSL, metastases, and high-grade glioma were given. FET-PET showed intense uptake in lesion on axial PET (f) and fused PET/CT (g) images with tumor-to-contralateral white mater (T/Wm) ratio of 2.4 and 2.5 at 5 and 20 min, favoring high-grade glioma. Histopathology was WHO Grade IV glioma -- glioblastoma](WJNM-18-266-g005){#F5}

![(a) Box plot and (b) dot plot depicting the tumor-to-white matter (T/Wm) ratio across PCNSL, metastases, glioblastoma, and other lesions](WJNM-18-266-g006){#F6}

![Area under the curve showing a 1.9 tumor-to-white matter (T/Wm) ratio cutoff to differentiate high-grade glial and nonglial high-grade lesions with a sensitivity of 93.8% and specificity of 91%, at 5 min (a) and 20 min (b). ROC: Receiver operating characteristic](WJNM-18-266-g007){#F7}

DISCUSSION {#sec1-4}
==========

PCNSL, metastases, and HGG are the three most common differentials for high-grade intracranial lesions seen in clinical practice. Accurate differentiation is of high value as the management protocols and prognosis for each of three conditions is altogether different.\[[@ref8][@ref9][@ref10]\] The objective of this study, therefore, was to assess the utility of FET-PET in detecting HGGs, when lesions did not demonstrate classical MRI features, in spite of high index of suspicion. Since we included just those patients who had equivocal MRI studies in spite of advanced sequences, the sample size was limited to 27 patients. We generated a cutoff of 1.9 for tumor-to-white matter ratio on FET-PET to distinguish between glial and nonglial lesions. Nonglial lesions included BM, PCNSL, two tuberculomas, and one anaplastic meningioma. Out of four patients with BM, two had primary in the lung, one as anorectal melanoma, and one in the breast. FET-PET, with a sensitivity and specificity of 93% and 91%, respectively, for diagnosing HGGs, has shown potential to be used in this clinical situation.

A meta-analysis by Dunet *et al*.,\[[@ref11]\] derived maximum tumor-to-background ratio (TBRmax) cutoff of 2.1 for differentiating glial and nonglial tumors. However, it had a modest sensitivity and specificity of 71% and 72%, primarily because gliomas across all grades were included in the study. Most studies using FET-PET have focused on its utility in grading gliomas.\[[@ref12]\] Conventional MRI has similar accuracy,\[[@ref13]\] for this purpose and recent literature with advanced magnetic resonance (MR) techniques have shown higher accuracy and specificity.\[[@ref14]\] This obviates the need for additional molecular imaging for grading of gliomas. However, for undiagnosed brain lesions, MR features are not always confirmatory. MRI findings of tumor infiltration and contrast enhancement can be seen in all three high-grade tumors. Diffusion-weighted imaging which is an index of cellularity of tumor may be nonspecific in some cases.\[[@ref15]\] Relative cerebral blood volume, a parameter on MR perfusion imaging, which offers the highest accuracy for distinguishing glioblastoma, metastases, and PCNSLs,\[[@ref16]\] has remarkable sensitivity but has modest specificity of 64%.\[[@ref17]\]

There have been studies with fluorodeoxyglucose (FDG) PET for characterizing high-grade lesions. Purandare *et al*. showed no difference in SUV~max~ values for HGG and BM whereas SUV~max~ of 15.5 showed sensitivity and specificity of 84% and 80% for diagnosing PCNSL.\[[@ref18]\] Two similar studies have shown the similar cutoff for detecting PCNSL, but false positives have been reported, owing to lack of specificity.\[[@ref19][@ref20]\] The need of specific tracer is important since not all lesions are amenable to biopsy, and treatment plans are based on imaging diagnosis. Radiolabeled amino acids such as methionine and FET show selectively high uptake in proliferating glial tissue but low uptake in normal brain tissue. FET uptake significantly correlates with tumor cell density and proliferation rate as well as with microvascular density and neoangiogenesis; all of these being pathological markers of HGGs.\[[@ref21]\] FET is not incorporated into metabolic pathway, and uptake is directly proportional to the density of LAT-2; which is overexpressed on proliferating glial cells and not present on inflammatory cell or other tumor types, making it specific for HGGs. FET localization is independent of the integrity of blood--brain barrier, thus nonenhancing lesions on MR can be characterized.\[[@ref22]\] Another important aspect is the impact of steroid on the uptake of FET. Unlike FDG-PET, in which uptake could be influenced by cumulative doses of corticosteroid before a PET scan, steroids do not significantly impact TBR values in FET-PET.\[[@ref23][@ref24]\] Unlike existing literature that proposes a dynamic imaging protocol, we preferred dual-point static acquisition (5 and 20 min), based on the study by Albert *et al*.\[[@ref25]\] Peak FET concentration in glial tumors occurs approximately at 20 min and declines slightly thereafter. 5-min image was acquired to assess the tumor perfusion, which shows an early peak in HGGs, with a small subset of lesions showing overestimation of FET uptake in early images due to high vascularity.\[[@ref26]\] Static 20-min image helps to confirm the findings on 5-min image as well as provides tumor extent. In addition, static acquisition improved patient compliance with shorter scanning time, avoiding motion artifacts. It led to reduction of scanning time per patient, which is crucial for high-volume PET/CT departments.

Rapp *et al*.\[[@ref27]\] derived a TBRmax cutoff of 2.5 to differentiate gliomas from other brain lesions. However, the clinical benefit was unclear as it included all brain lesions, including high- and low-grade gliomas, which brought down the sensitivity to 57%. Since molecular imaging using PET involves target-specific tracers, the clinical question that is to be answered is of utmost importance. Our study was thereby designed to address a practical clinical issue faced in neuro-oncology clinic of a large tertiary care hospital. The retrospective nature and small cohort are the limitations; however, with the results of this study, a larger prospective study can be designed to generate more robust results.

CONCLUSION {#sec1-5}
==========

FET-PET has shown potential to become the modality of choice for detecting high-grade glial tumors from other high-grade brain lesions when the MRI features are equivocal.
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